Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GW Pharmaceuticals' Sativex oromucosal spray received recommendation for national approval in six European countries.
Subscribe to our email newsletter
GW Pharma and Almirall have completed European Mutual Recognition Procedure (MRP) for Sativex in the treatment of spasticity due to Multiple Sclerosis (MS).
The companies have already received approval for this MS drug in the UK and Spain.
With the completion of MRP, now the companies are anticipating to get approvals in Germany, Italy, Denmark, Sweden, Austria and the Czech Republic.
Almirall chief scientific officer Bertil Lindmark said Sativex is the first drug which provides MS patients with a treatment option to mitigate spasticity and other related symptoms.